環(huán)加氧酶2(COX 2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)
Multiplex Assay Kit for Cyclooxygenase-2 (COX 2) ,etc. by FLIA (Flow Luminescence Immunoassay)
PGG/HS; PGHS2; PHS2; HCox2; PTGS2; Prostaglandin Endoperoxide Synthase 2; Prostaglandin G/H Synthase And Cyclooxygenase; Prostaglandin H2 synthase 2
(注:?jiǎn)未位鞙y(cè)多因子不超過8個(gè)指標(biāo) )
- 編號(hào)LMA699Ra
- 物種Rattus norvegicus (Rat,大鼠) 相同的名稱,不同的物種。
- 實(shí)驗(yàn)方法雙抗夾心
- 反應(yīng)時(shí)長(zhǎng)3.5h
- 檢測(cè)范圍0.01-10ng/mL
- 靈敏度最小可檢測(cè)劑量小于等于0.003 ng/mL.
- 樣本類型Serum, plasma, tissue homogenates and other biological fluids.
- 下載 英文說明書 中文說明書
- 規(guī)格 8指標(biāo)數(shù) 7指標(biāo)數(shù) 6指標(biāo)數(shù) 5指標(biāo)數(shù) 4指標(biāo)數(shù) 3指標(biāo)數(shù) 2指標(biāo)數(shù)1指標(biāo)數(shù)
- 價(jià)格 ¥ 2562 ¥ 2660 ¥ 2808 ¥ 3005 ¥ 3202 ¥ 3497 ¥ 3941 計(jì)算器 ¥ 4926 添加到價(jià)格計(jì)算器
- 欲了解實(shí)際交易價(jià)格和更多情況,請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
特異性
本試劑盒用于檢測(cè)環(huán)加氧酶2(COX 2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),經(jīng)檢測(cè)與其它相似物質(zhì)無明顯交叉反應(yīng)。
由于受到技術(shù)及樣本來源的限制,不可能完成對(duì)所有相關(guān)或相似物質(zhì)交叉反應(yīng)檢測(cè),因此本試劑盒有可能與未經(jīng)檢測(cè)的其它物質(zhì)有交叉反應(yīng)。
回收率
分別于定值血清及血漿樣本中加入一定量的環(huán)加氧酶2(COX 2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)(加標(biāo)樣品),重復(fù)測(cè)定并計(jì)算其均值,回收率為測(cè)定值與理論值的比率。
樣本 | 回收率范圍(%) | 平均回收率(%) |
serum(n=5) | 89-101 | 96 |
EDTA plasma(n=5) | 79-95 | 90 |
heparin plasma(n=5) | 87-101 | 98 |
sodium citrate plasma(n=5) | 78-98 | 91 |
精密度
精密度用樣品測(cè)定值的變異系數(shù)CV表示。CV(%) = SD/mean×100
批內(nèi)差:取同批次試劑盒對(duì)低、中、高值定值樣本進(jìn)行定量檢測(cè),每份樣本連續(xù)測(cè)定20 次,分別計(jì)算不同濃度樣本的平均值及SD值。
批間差:選取3個(gè)不同批次的試劑盒分別對(duì)低、中、高值定值樣本進(jìn)行定量測(cè)定,每個(gè)樣本使用同一試劑盒重復(fù)測(cè)定8次,分別計(jì)算不同濃度樣本的平均值及SD值。
批內(nèi)差: CV<10%
批間差: CV<12%
線性
在定值血清及血漿樣本內(nèi)加入適量的環(huán)加氧酶2(COX 2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法),并倍比稀釋成1:2,1:4,1:8,1:16的待測(cè)樣本,線性范圍即為稀釋后樣本中環(huán)加氧酶2(COX 2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)含量的測(cè)定值與理論值的比率。
樣本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 92-105% | 93-101% | 99-105% | 79-103% |
EDTA plasma(n=5) | 84-102% | 90-99% | 91-103% | 80-104% |
heparin plasma(n=5) | 98-105% | 86-101% | 90-99% | 93-101% |
sodium citrate plasma(n=5) | 98-105% | 95-102% | 94-102% | 78-94% |
穩(wěn)定性
經(jīng)測(cè)定,試劑盒在有效期內(nèi)按推薦溫度保存,其活性降低率小于5%。
為減小外部因素對(duì)試劑盒破壞前后檢測(cè)值的影響,實(shí)驗(yàn)室的環(huán)境條件需盡量保持一致,尤其是實(shí)驗(yàn)室內(nèi)溫度、濕度及溫育條件。其次由同一實(shí)驗(yàn)員來進(jìn)行操作可減少人為誤差。
實(shí)驗(yàn)流程
1. 實(shí)驗(yàn)前標(biāo)準(zhǔn)品、試劑及樣本準(zhǔn)備;
2. 加樣(標(biāo)準(zhǔn)品、樣本、磁珠)標(biāo)準(zhǔn)品或樣本100μL及磁珠10μL,
37°C酶標(biāo)板振蕩器孵育90分鐘;
3. 磁吸甩干,加檢測(cè)溶液A100μL,37°C酶標(biāo)板振蕩器孵育60分鐘;
4. 磁吸洗板3次;
5. 加檢測(cè)溶液B100μL,37°C振動(dòng)孵育30分鐘;
6. 磁吸洗板3次;
7. 加鞘液100μL,旋渦震蕩2分鐘后讀數(shù)。
實(shí)驗(yàn)原理
將環(huán)加氧酶2(COX 2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體包被于磁珠,制成固相載體,向微孔中分別加入標(biāo)準(zhǔn)品或標(biāo)本以及磁珠,其中的環(huán)加氧酶2(COX 2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)與連接于固相載體上的抗體結(jié)合,然后加入生物素化的環(huán)加氧酶2(COX 2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)抗體,將未結(jié)合的生物素化抗體洗凈后,加入PE標(biāo)記的親和素,再次徹底洗滌后即可上機(jī)讀數(shù)。MFI值和樣品中的環(huán)加氧酶2(COX 2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法)呈正相關(guān)。
贈(zèng)品
相關(guān)產(chǎn)品
編號(hào) | 適用物種:Rattus norvegicus (Rat,大鼠) | 應(yīng)用(僅供研究使用,不用于臨床診斷!) |
RPA699Ra01 | 環(huán)加氧酶2(COX 2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAA699Ra01 | 環(huán)加氧酶2(COX 2)多克隆抗體 | WB; IHC; ICC; IP. |
MAA699Ra21 | 環(huán)加氧酶2(COX 2)單克隆抗體 | WB; IHC; ICC; IP. |
SEA699Ra | 環(huán)加氧酶2(COX 2)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMA699Ra | 環(huán)加氧酶2(COX 2)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
雜志 | 參考文獻(xiàn) |
Photodermatology, Photoimmunology & Photomedicine | Diallyl sulfide protects against ultraviolet B-induced skin cancers in SKH-1 hairless mouse: analysis of early molecular events in carcinogenesis [Wiley: source] |
Skin Cancer - MedlinePlus Health Information | Molecular mechanisms underlying chemopreventive activities of glycyrrhizic acid against UVB-radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis [PubMed: 21545294] |
Evidence-Based Complementary and Alternative Medicine | Curcumin Protects against UVB-Induced Skin Cancers in SKH-1 Hairless Mouse: Analysis of Early Molecular Markers in Carcinogenesis [PubMed: 22888366] |
Integrative Cancer Therapies | Decalepis hamiltonii inhibits tumor progression and metastasis by regulating the inflammatory mediators and nuclear factor κB subunits [Pubmed: 24013642] |
Journal of ethnopharmacology | Multitargeted protective effect of Abacopteris penangiana against carrageenan-induced chronic prostatitis in rats. [Pubmed: 24211397] |
Int J Clin Exp Pathol | Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells [PubMed: 26464643] |
Int J Clin Exp Pathol | Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma [PubMed: 26191267] |
Journal of Biomechanics | The shear wave elastic modulus and the increased nuclear factor kappa B(NF-kB/p65) and cyclooxygenase-2 (COX-2) expression in the area of myofascial trigger points activated in a rat model by blunt trauma to the vastus medialis [pubmed:29137729] |
Journal of Global Pharma Technology | Inflammatory Response of Annona Muricata Linn Leaves Extract in Colorectal Cancer Patients [NCT02439580] |
International?Journal?of?Molecular?Sciences | High Expression of IL-1RI and EP2 Receptors in the IL-1β/COX-2 Pathway, and a New Alternative to Non-Steroidal Drugs—Osthole in Inhibition COX-2 [Pubmed: 30620999] |
International Immunopharmacology | A novel concept of immunological and allergy interactions in Autism Spectrum Disorders: Molecular, anti-inflammatory effect of osthole [Pubmed: 30953868] |
Reports of Biochemistry & Molecular Biology | Evaluation of Serum Cyclooxygenase, Hepcidin Levels in Acute Renal Injury (AKI) Patients Following Cardiac Catheterization [] |
J Ethnopharmacol | Isolation and characterization of anti-inflammatory and anti-proliferative compound, for B-cell Non-Hodgkin lymphoma, from Nyctanthes arbor-tristis Linn. [Pubmed:35398498] |